All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Join our

Live Symposium

How to sequence BCMA-directed therapies in early relapsed/ refractory multiple myeloma

At the ESH 7th Translational Research Conference:

Multiple Myeloma

with Martin Kaiser, Mohamad Mohty, and Rakesh Popat

Saturday, October 5, 2024 | 09:10-10:10 CEST

Register now

This independent educational activity is funded by GSK. All content is developed independently by the faculty. The funders are allowed no influence on the content of this activity.

  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2023-01-30T11:27:43.000Z

Initial results of daratumumab + lenalidomide in frail patients: The IFM 2017-03 trial

Jan 30, 2023
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in the management of patients with newly diagnosed multiple myeloma.

The International Myeloma Foundation (IFM) 2017-03 (IFM 2017-03) trial (NCT03993912) is a phase III clinical trial exploring the use of daratumumab and lenalidomide (DR) compared with lenalidomide and dexamethasone (Rd) for the treatment of patients with newly diagnosed multiple myeloma (NDMM) ineligible for transplant.1

The Multiple Myeloma Hub is pleased to summarize the oral presentation given by Manier1 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, which detailed outcome and safety data from the IFM 2017-03 trial. Their research question was: does the benefit of dexamethasone justify potentially higher rates of infection and pneumonia in frail patients?1

Study design

The IFM 2017-03 trial randomized patients to Rd versus DR in the ratio 1:2. All patients had NDMM, were ≥65 years, and had an IFM frailty score of ≥2 (calculated using age, Eastern Cooperative Oncology Score, and Charlson Comorbidity Index).2 The study design can be seen in Figure 1. Treatment in both arms was given until disease progression or unacceptable toxicity, with low dose dexamethasone (20 mg/week) in Arm B.

Figure 1. Study design of the IFM 2017-03 trial* 

C, Cycle; Dara, daratumumab; Dex, dexamethasone; DR, lenalidomide and dexamethasone; IFM, International Myeloma Foundation; Len, lenalidomide; Lo-Dex, low-dose dexamethasone; LT, long-term; NDMM, newly diagnosed multiple myeloma; OS, overall survival; PD, progressive disease; Rd, lenalidomide and low-dose dexamethasone; SC, subcutaneous.
*Adapted from Manier.1

This pre-planned interim analysis included overall response rate, very good partial response or better (≥VGPR), minimal residual disease (MRD) rate, and the occurrence of ≥Grade 3 adverse events. Longer follow-up is ongoing to evaluate progression-free survival assessed up to 84 months (primary endpoint), as well as time-to-treatment failure, time-to-next treatment, and overall survival, among other secondary outcomes.

Results

In total, 295 patients were recruited, with 199 in the DR arm compared with 94 in the Rd arm. Patient disposition can be seen in Figure 2. In total, 3 patients dropped out prior to treatment. For the analysis presented, data cut off was performed at 12 months, with a higher percentage of Rd patients discontinuing treatment compared with DR patients (Figure 2).

Figure 2. Patient disposition of patients recruited to IFM 2017-03* 

DR, lenalidomide and daratumumab; IFM; International Myeloma Foundation; Rd, lenalidomide and dexamethasone.
*Adapted from Manier.1

Patient demographics can be seen in Table 1, showing that patients in both groups were well matched for age and frailty.

Table 1. Patient data from the IFM 2017-03 trial*

Characteristic, %

Patients treated with DR
(n = 199)

Patients treated with Rd
(n = 94)

Age ≥80 years

59

65

Sex

 

 

              Female

51

51

              Male

49

49

ECOG

 

 

              0

10

10

              1

46

50

              2

44

40

IFM frailty score

 

 

              ≤1

0

0

              2

29

37

              3

41

28

              4

22

26

              5

9

10

ISS disease stage

 

 

              I

17

19

              II

51

53

              III

32

28

Cytogenetic risk profile

 

 

              Standard

83

78

              High

17

22

DR, lenalidomide and dexamethasone; ECOG, Eastern Cooperative Oncology Group; IFM, International Myeloma Foundation; ISS, International Staging System; Rd, lenalidomide and dexamethasone.
*Adapted from Manier.1

The analysis presented was from a data cut-off of 12 months:

  • Overall response rate was 96% in the DR group compared with 85% in the Rd group (p = 0.001), with a ≥VGPR rate of 64% vs 43%, respectively, that improved over time.
  • MRD assessment by next generation sequencing at 10−5 was performed in patients with ≥VGPR at 12 months and patients with missing MRD data were considered positive. At a 10−5 sensitivity in an intention-to-treat interim analysis, DR significantly improved rates of MRD negativity compared with Rd (10% vs 3%; p = 0.012).
  • Safety data can be seen in Table 2. Treatment discontinuation due to adverse events for DR and Rd were 14% and 16%, respectively, with no statistically significant difference.

Table 2. Grade ≥3 adverse events in the IFM 2017-03 trial*

Characteristic, %

DR group
(n = 199)

Rd group
(n = 94)

p value

All Grade ≥3 AEs

82

68

0.010

SAE

55

63

0.21

Hematologic

55

26

<0.0001

    Neutropenia

46

18

<0.0001

              Anemia

11

2

0.010

              Thrombocytopenia

9

3

0.089

Infection

13

8

0.29

Non-COVID infections

9

14

0.21

COVID

5

4

1

              Pneumonia

3

7

0.060

AE, adverse event; DR, lenalidomide and dexamethasone; IFM, International Myeloma Foundation; Rd, lenalidomide and dexamethasone; SAE, serious adverse event.
*Adapted from Manier.1

Higher rates of infection were seen in patients with ≥4 IFM frailty score in both the DR (21%) and Rd (27%) groups, relative to patients with a IFM frailty score of 23 (9% and 13%, respectively). Manier comments on a trend towards higher rates of infection in patients with increased frailty in both arms but notes that there were no statistical significance in either.

Conclusion

The IFM 2017-03 trial is a novel phase III clinical trial exploring the possibility of avoiding steroid use for the treatment of frail patients with NDMM. This interim analysis suggests superior rates of ≥VGPR and MRD negativity in patients treated with DR compare with Rd. Safety data for both treatments is comparable to date, with no increased risk of infection or pneumonia with DR despite the significant increase of neutropenia. Further follow-up is ongoing to determine if frail patients with NDMM can be safely treated without steroid-containing regimens.

  1. Manier S. A dexamethasone sparing-regimen with daratumumab and lenalidomide in frail patients with newly-diagnosed multiple myeloma: Efficacy and safety analysis of the phase 3 IFM2017-03 trial. Oral abstract #569. 64th American Society of Hematology Annual Meeting and Exposition; Dec 11, 2022; New Orleans, US.
  2. Facon T, Dimopoulos MA, Meuleman N, et al. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. Leukemia. 2020;34(1):224-233. DOI: 1038/s41375-019-0539-0

Your opinion matters

HCPs, what is your preferred format for educational content on the Multiple Myeloma Hub?
39 votes - 30 days left ...

Related articles

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox